Showing 1 - 10 of 1,692
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372
To understand how global firm networks operate, we need consistent information on their activities, unbiased by their reporting choices. In this paper, we collect a novel dataset on the light that factories emit at night for a large sample of car manufacturing plants. We show that nightlight...
Persistent link: https://www.econbiz.de/10013177119
Geo-political tensions and disruptions to global value chains have led policy makers to re-evaluate their approach to globalisation. Many countries are considering friend-shoring - trading primarily with countries sharing similar values - as a way of minimising exposure to weaponisation of trade...
Persistent link: https://www.econbiz.de/10014450552
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …
Persistent link: https://www.econbiz.de/10011509446
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …
Persistent link: https://www.econbiz.de/10010473542
We construct an asymmetri c duopolistic R&D and production behavior model subject to knowledge spillovers. This model is an extension to the symmetric model of d'Aspremont and Jacquemin (A&J (1988)) and aims to determine the cooperative and non-cooperative R&D strategies for two agents of...
Persistent link: https://www.econbiz.de/10009781563
Multinational enterprises are often accused to have a preference for investing in countries in which the working populations' civil and political rights are largely disregarded. This paper presents an empirical investigation of the popular political repression boosts FDI hypothesis and arrives...
Persistent link: https://www.econbiz.de/10011397998
Using a panel of Spanish manufacturing firms covering the 1990-2017 period, I document new evidence about affiliates of multinational enterprises (MNEs): after being acquired, they exhibit a higher propensity to use robots, which leads to a reduction in their labor share. These effects are...
Persistent link: https://www.econbiz.de/10015077751